blood cancer

Lava, smoldering from dropping lead asset, lays off 30% of staff to save cash
Fierce Biotech
Tue, 02/25/25 - 10:52 am
Lava Therapeutics
blood cancer
LAVA-1266
layoffs
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida
Pharma Live
Wed, 01/8/25 - 11:25 am
Roche
M&A
Poseida Therapeutics
blood cancer
Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup
Fierce Biotech
Tue, 12/10/24 - 11:32 am
Lava Therapeutics
clinical trials
LAVA-1207
prostate cancer
blood cancer
Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl
Fierce Biotech
Tue, 12/3/24 - 11:00 am
Takeda
Keros Therapeutics
blood cancer
cancer
Reblozyl
Bristol Myers Squibb
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports
Fierce Pharma
Mon, 12/2/24 - 07:46 pm
Bluebird Bio
Skysona
gene therapy
FDA
blood cancer
cALD
FDA puts hold on Gilead's blood cancer therapy trials
Reuters
Wed, 02/7/24 - 09:20 pm
Gilead Sciences
FDA
clinical trials
magrolimab
blood cancer
ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner for PTCL drug
Fierce Biotech
Mon, 12/11/23 - 10:09 am
AstraZeneca
Dizal Pharmaceutical
blood cancer
peripheral T cell lymphoma
golidocitinib
clinical trials
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Mon, 11/20/23 - 10:12 am
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
Bristol Myers pays $100M for a different kind of ADC
BioPharma Dive
Mon, 11/6/23 - 09:54 am
Bristol Myers Squibb
antibody-drug conjugate
bone cancer
blood cancer
Orum Therapeutics
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
Fierce Biotech
Fri, 08/11/23 - 10:09 am
Gilead Sciences
ALX Oncology
blood cancer
clinical trials
anti-CD47
evorpacept
Amgen granted full FDA approval for blood cancer treatment
Biopharma Reporter
Thu, 06/22/23 - 10:10 am
Amgen
Blincyto
FDA
blood cancer
Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug
BioPharma Dive
Fri, 06/16/23 - 09:57 am
Roche
Columvi
FDA
relapsed or refractory diffuse large B-cell lymphoma
blood cancer
FDA delays approval decision on GSK's $1.9B blood cancer bet
Fierce Biotech
Fri, 06/16/23 - 09:52 am
GSK
FDA
momelotinib
blood cancer
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
Fri, 06/16/23 - 09:44 am
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug
Fierce Biotech
Tue, 06/6/23 - 10:01 am
Foghorn Therapeutics
FHD-286
FDA
blood cancer
Allogeneic cell therapy approval to pave the way for future therapies in this class
Clinical Trials Arena
Mon, 05/1/23 - 10:05 am
Gamida Cell
stem cell transplant
Omisirge
blood cancer
FDA
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Thu, 01/26/23 - 10:40 am
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
With new data, Nkarta builds case for ‘natural killer’ cell therapy
BioPharma Dive
Mon, 12/5/22 - 10:45 am
Nkarta Therapeutics
cancer
blood cancer
natural killer cell therapies
NKX019
Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule
Fierce Pharma
Tue, 11/22/22 - 04:41 pm
Jazz Pharmaceuticals
FDA
Rylaze
blood cancer
acute lymphoblastic leukemia
lymphoblastic lymphoma

Pages